Comparing the Effects of SVF-Enriched PRP and Standard PRP for Treating Male Pattern Baldness

Comparative study to know the efficacy and safety of stromal vascular fraction-enriched platelet-rich plasma therapy versus platelet rich plasma therapy in the treatment of Androgenetic alopecia - NIL

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/03/083278

Enrollment

Registered

2025-03-24

Start date

Unknown

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L649- Androgenic alopecia, unspecified Health Condition 2: 8- Other Procedures

Interventions

Intervention1: Stromal vascular fraction enriched Platelet rich plasma (SVF +PRP): SVF + PRP once a month for 3 months Control Intervention1: PRP: PRP once a month for 3 months

Eligibility

Inclusion criteria

Inclusion criteria: 1.Hamilton score 2-6 in male patients,ludwing score 1-3 in female patients 2.patients not on any treatment for androgenetic alopecia for past 1 month.

Exclusion criteria

Exclusion criteria: 1 Patient with malignancy, autoimmune disease 2 Pregnancy 3 History of keloid formation 4 Patients with platelet disorders, thrombocytopenia, sepsis. 5 Patients currently on anticoagulant therapy, 6 Patients on chemotherapy during the last 5years

Design outcomes

Primary

Measure	Time frame
Hair growth is the primary outcome the improvement will be assessed using pre ? and post ? treatment photographs, Physicians global assessment (PhGAS) scores, Patients global assessment score(PaGAS) and trichoscan.Timepoint: 3 weeks	—

Secondary

Measure	Time frame
Alopecia quality of life assessment will be assessed by using dermatology life quality index(DLQI).Timepoint: Baseline,12 weeks & 16 weeks.	—

Countries

India

Contacts

Public ContactDr Leena Raveendra

Rajarajeshwari medical college and hospital

cbleena@gmail.com9845103089

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026